Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

A noninferiority study is often used to investigate whether a treatment's efficacy or safety profile is acceptable compared with an alternative therapy regarding the time to a clinical event. The empirical quantification of the treatment difference for such a study is routinely based on the hazard ratio (HR) estimate. The HR, which is not a relative risk, may be difficult to interpret clinically, especially when the underlying proportional hazards assumption is violated. The precision of the HR estimate depends primarily on the number of observed events but not directly on exposure times or sample size of the study population. If the event rate is low, the study may require an impractically large number of events to ensure that the prespecified noninferiority criterion for the HR is attainable. This article discusses deficiencies in the current approach for the design and analysis of a noninferiority study. Alternative procedures are provided, which do not depend on any model assumption, to compare 2 treatments. For a noninferiority safety study, the patients' exposure times are more clinically important than the observed number of events. If the patients' exposure times are long enough to evaluate safety reliably, then these alternative procedures can effectively provide clinically interpretable evidence on safety, even with relatively few observed events. These procedures are illustrated with data from 2 studies. One explores the cardiovascular safety of a pain medicine; the second examines the cardiovascular safety of a new treatment for diabetes. These alternative strategies to evaluate safety or efficacy of an intervention lead to more meaningful interpretations of the analysis results than the conventional strategy that uses the HR estimate.

[1]  Lihui Zhao,et al.  Predicting the restricted mean event time with the subject's baseline covariates in survival analysis. , 2014, Biostatistics.

[2]  A. Katz,et al.  Cardiovascular Outcome Studies With Novel Antidiabetes Agents: Scientific and Operational Considerations , 2013, Diabetes Care.

[3]  Yoshiaki Uyama,et al.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  I. Raz,et al.  Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs , 2011, Diabetes Care.

[5]  Erik T. Parner,et al.  Regression Analysis of Censored Data Using Pseudo-observations , 2010 .

[6]  Miguel A Hernán,et al.  The hazards of hazard ratios. , 2010, Epidemiology.

[7]  Sanjay Kaul,et al.  Non-inferiority study design: lessons to be learned from cardiovascular trials. , 2012, European heart journal.

[8]  R. D'Agostino,et al.  Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics , 2002, Statistics in medicine.

[9]  J. Schumi,et al.  TRIALS REVIEW Open Access , 2022 .

[10]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[11]  John P. Klein,et al.  SAS and R functions to compute pseudo-values for censored data regression , 2008, Comput. Methods Programs Biomed..

[12]  Patrick Royston,et al.  Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome , 2013, BMC Medical Research Methodology.

[13]  William Checkley,et al.  Multilevel competing risks in the evaluation of nosocomial infections: time to move on from proportional hazards and even from hazards altogether , 2014, Critical Care.

[14]  R. Garrick A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease , 2010 .

[15]  L. Kux OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 2014 .

[16]  P. Royston,et al.  The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt , 2011, Statistics in medicine.

[17]  S. Kaul,et al.  The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. , 2013, The New England journal of medicine.

[18]  Lihui Zhao,et al.  Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study , 2012, Clinical trials.

[19]  D. Harrington,et al.  Counting Processes and Survival Analysis , 1991 .

[20]  Nicky J Welton,et al.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.

[21]  L J Wei,et al.  Nonparametric estimation for the difference or ratio of median failure times. , 1993, Biometrics.

[22]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[23]  S. Solomon,et al.  Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas , 2006, Circulation.

[24]  S. Solomon,et al.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.

[25]  David M. Zucker,et al.  Restricted Mean Life with Covariates: Modification and Extension of a Useful Survival Analysis Method , 1998 .

[26]  Michael Parzen,et al.  Simultaneous Confidence Intervals for the Difference of Two Survival Functions , 1997 .

[27]  D.,et al.  Regression Models and Life-Tables , 2022 .

[28]  Lee-Jen Wei,et al.  The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. , 1992, Statistics in medicine.